Please assess the completion status of the following clinical trial:

Trial Title: Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of hemophilia A or B~* Either on a stable prophylaxis regimen for their bleeding disorder (factor, bypassing agent, or nonfactor product therapy) OR currently taking or agree to initiate a gastroprotective agent (esomeprazole) for the duration of the trial~* Diagnosis of Hemophilic Arthopathy for at least 6 months prior to screening~* Chronic symptomatic pain in one or more joint(s) on 20 of the 30 days prior to screening.~* Able and willing to wash out of non-study analgesic medications/agents for at least 7 days prior to Randomization including: acetaminophen (paracetamol), NSAIDs, opioids, cannabinoids, topical analgesics, benzodiazepines, gabapentin/pregabalin-containing products and other antiepileptic drugs used for pain~* Primary source of pain is due to Hemophilic Arthropathy~Exclusion Criteria:~* Taking opioids for greater than 4 days per week prior to screening~* Has a history of advanced renal disease or severe liver disease (within the last 6 months)~* Receiving emicizumab while also receiving activated prothrombin complex concentrate (FEIBA)~* Uncontrolled or poorly controlled hypertension~* History of major cardiac or cerebrovascular disease~* History of an upper GI perforation, obstruction, or major GI bleed or current evidence of GI bleeding~* Has active hepatitis C or hepatitis B infection or uncontrolled HIV. Note: Patients who are HIV positive are allowed to participate if considered to be controlled.~* Has a positive drug screen for all prohibited drugs of potential abuse at screening~* Has had an intra-articular injection (within 3 months), initiated physical therapy (within 30 days) or has had orthopedic surgery (within 4 months) prior to screening

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TRM-201 (Rofecoxib) (Type: EXPERIMENTAL): 1 TRM-201 tablet taken orally once daily for 12 weeks in Part I and orally once daily for an additional 52 weeks in Part II
- Placebo (Type: PLACEBO_COMPARATOR): 1 placebo tablet (to match TRM-201) taken orally once daily for 12 weeks in Part I and then 1 TRM-201 tablet taken orally once daily for an additional 52 weeks in Part II

Based on this trial design, predict the completion outcome and termination type (if applicable).